iFANN
    Last updated
    Ionis Pharmaceuticals
    Biotechnology, Pharmaceutical Research

    Ionis Pharmaceuticals

    United States flagUnited States

    "Advancing RNA-targeted medicines for serious diseases"

    Founded 1989 Carlsbad, California CEO: Robert M. Collins
    Community

    About

    Ionis Pharmaceuticals operates as a biotechnology firm headquartered in Carlsbad, California, dedicated to developing and commercializing RNA-targeted therapies. The organization originally launched under the name Isis Pharmaceuticals in 1989 before rebranding in late 2015 to signal its expansion beyond antisense technology into RNA interference and CRISPR-based approaches.

    The company markets five approved medicines as of 2026, including Spinraza (nusinersen) for spinal muscular atrophy and Inotersen (Tegsedi) for hereditary transthyretin-mediated amyloidosis. Its proprietary platform enables precise gene silencing, addressing rare genetic disorders affecting the nervous system, cardiovascular health, and metabolic functions.

    Products & Sub-brands

    Spinraza (nusinersen)Tegsedi (inotersen)VolanesorsenRG-6299IONIS-FXLRx-S

    Frequently Asked Questions

    Who owns Ionis Pharmaceuticals?
    Ionis Pharmaceuticals is a publicly traded company listed on the NASDAQ under the ticker symbol IONS, meaning it is owned by its shareholders.
    Who is the CEO of Ionis Pharmaceuticals?
    Robert M. Collins serves as the Chief Executive Officer as of 2026.
    Is Ionis Pharmaceuticals still in business?
    Yes, the company remains active with five approved drugs and an ongoing pipeline of investigational therapies.
    What are Ionis Pharmaceuticals' top competitors?
    Key competitors include Alnylam Pharmaceuticals, Biogen, Regeneron, and Novartis.
    How much is Ionis Pharmaceuticals worth?
    Valuation fluctuates daily; analyst projections in August 2026 estimated a fair value between $60 and $94 per share.

    Keywords

    biotechnologyRNA therapeuticsantisense therapyrare diseasesspinal muscular atrophygene silencingCRISPRNusinersenInotersen

    Sources

    Ionis Pharmaceuticals Official SiteWikipediaUS News InvestingNews-MedicalSimply Wall St

    Company Info

    Founded
    1989
    Founder
    Michael R. McGee, Philip A. Sharp
    CEO
    Robert M. Collins
    Headquarters
    Carlsbad, California
    Industry
    Biotechnology, Pharmaceutical Research
    Former Name
    Isis Pharmaceuticals
    Rebrand Date
    Late 2015
    Stock Ticker
    IONS
    Exchange
    NASDAQ
    Approved Drugs (2026)
    5
    Headquarters Location
    Carlsbad, California

    Official Website

    www.ionis.com/

    Links

    Join the community

    fans discussing